Search results for "Deflazacort"

showing 2 items of 2 documents

Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study

1995

Several studies have demonstrated the slowing effect of corticosteroids on the decline of muscle strength in Duchenne muscular dystrophy (DMD). Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED). An ongoing double blind multicenter study is comparing the effects and side effects of deflazacort (0.9 mg/kg/day) and prednisone (0.75 mg/kg/day) in DMD. This interim report includes data for 67 boys between age 5 years and loss of ambulation. Besides the common clinical and laboratory data for chronic corticoid treatment, motor performance has been tested. Interim results, 3-15 months after starting the medication, show some scattering but no grouping of data for all …

Malemedicine.medical_specialtyDuchenne muscular dystrophyAnti-Inflammatory AgentsMuscular DystrophiesDouble-Blind MethodDevelopmental NeurosciencePregnenedionesPrednisoneInternal medicinemedicineHumansChildCreatine KinaseDose-Response Relationship Drugbiologybusiness.industryBody WeightGeneral MedicineAlkaline Phosphatasemedicine.diseaseClinical trialDeflazacortDose–response relationshipEndocrinologyNeurologyMulticenter studyChild PreschoolAnesthesiaPediatrics Perinatology and Child HealthOsteocalcinbiology.proteinPrednisoneNeurology (clinical)medicine.symptombusinessWeight gainMuscle Contractionmedicine.drugBrain and Development
researchProduct

Deflazacort in Duchenne dystrophy: Study of long-term effect

1994

A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…

medicine.medical_specialtyPatient DropoutsTime Factorsmedicine.drug_classPhysiologyDuchenne muscular dystrophymedicine.medical_treatmentMotor ActivityPlaceboMuscular Dystrophieslaw.inventionCellular and Molecular NeuroscienceDouble-Blind MethodRandomized controlled trialPregnenedioneslawPhysiology (medical)medicineHumansChildGaitChemotherapybusiness.industryMusclesAnti-Inflammatory Agents Non-SteroidalBody Weightmedicine.diseaseSurgeryClinical trialDeflazacortAnesthesiaCorticosteroidNeurology (clinical)medicine.symptombusinessWeight gainFollow-Up Studiesmedicine.drugMuscle &amp; Nerve
researchProduct